Introduction
FHRs bind to C3b, iC3b, and C3dg, but provided no evidence of cofactor activity for the FI-143 mediated proteolysis of C3b or AP C3 convertase decay accelerating activities [10, 11] . These 144 studies also failed to detect any significant interaction of FHR-1 with C5 [10] , indicating that 145 FHR-1, FHR-2 and FHR-5 have no intrinsic C3 or C5 regulatory activity at physiological 146 concentrations. On the other hand, these experiments showed that the FHR-1, -2 and -5 147 proteins, through their ability to compete with FH for binding to C3b, actually prevent FH-148 mediated complement regulation. This interference with the FH regulatory activities is 149 apparently facilitated by their oligomerization, which increases avidity for their ligands, and is 150 significantly enhanced by the rare C3G-associated mutations that results in abnormal 151 multimerization of the FHR-1, FHR-2 and FHR-5 proteins [10, 11] . Importantly, it has been 152 reported that FHR-3 and FHR-4 are also able to compete for FH ligands and therefore have 153 the potential to interfere with FH regulation [41, 46] . 154
In addition to playing important roles in controlling FH activities on self, FH and some of 155 the FHRs have also been found to interact with several microbes and microbial proteins. 156
However, only few studies have addressed the functional consequences of the interaction of 157 the FHR proteins with pathogens. These studies showed that none of the bound FHRs (FHR-158 1, FHR-2 and FHR-5) conferred protection from complement activation and deposition of 159 C3b and C5b-9, whereas binding of FH could reduce or completely block C3b and C5b-9 160 deposition and lysis [47] . This suggests that FH but not the FHRs protect the microbes from 161 opsonophagocytosis and/or complement-mediated damage when bound on the microbial 162 surface. Strikingly, the FH domains that are well conserved among the FHRs are those that 163 Very recent experiments with the major human pathogen Neisseria meningitidis provide 168 strong support to these ideas [46] 
molecules. 198
The main function of FH/FHL-1 is to control the AP amplification loop and to prevent 199 tissue damage by accidental complement activation on self-surfaces. Basically, the role of and FHR-1 has identical pathogenic consequences to that of the disease-associated FH 209 mutations that disrupt the C-terminal functionalities ( Figure 3A) . Therefore, despite there are 210 only two amino acid differences (S1191L, V1197A) between the C-terminal regions of FH 211
and FHR-1, these differences are sufficient to alter sialic acid recognition [57], conferring 212 distinct surface binding specificity to FH and FHR-1 and eliminating the risk of an 213 undesirable competition between them for host tissues. The possibility that the FH/FHR 214 competition affects mainly a specific subset of surfaces, which does not include normal hostthose present on the surface of pathogens. This proposal assumes that there must be 220 complement activation and C3 deposition on these surfaces (spontaneous, following a trigger, 221 or both) that would be accelerated in the presence of these FHR proteins. between FH and FHRs may occur. We speculate that this competition would be further 289 enhanced by the deposition of the C3 activated fragments generated by activation of the lectin 290 pathway [76] . The advantage of individuals carrying the CFHR3-CFHR1 deletion would be to 291 have less FHRs to interfere with the regulation by FH of the complement activation induced 292 by these (Gd-IgA1)-antiglycan immune complexes in the kidney. 293
Complement also plays an important role in SLE, a severe autoimmune disease 294 characterized by the presence of autoantibodies that result in tissue injury of multiple organs 295
[24]. Here, in contrast to AMD and IgAN, the CFHR3-CFHR1 deletion represents an 296 important predisposition factor, suggesting that in this case decreased FH/FHR competition isdeleterious. Two possibilities have been proposed to explain this association; one is based on 298 the capacity of FHR-1 to inhibit C5 convertase activity and MAC formation, a role of FHR-1 299 that is currently controversial. The second explanation relates to the possibility that carriers of 300 the CFHR3-CFHR1 deletion generate autoantibodies against FH, similarly to the situation in 301 aHUS where these antibodies are associated with the homozygous deficiency of FHR-1 [77] . 302
The contrasting phenotypic association of SLE with the CFHR3-CFHR1 deletion, opposing 303 the protective effect observed for IgAN and AMD, may also suggest that some AP activation 304 could be beneficial in SLE. For example, the CFHR3-CFHR1 deletion may result in less 305 opsonization and opsonophagocytic removal of autoantigens due to increased complement 306 regulation by FH on apoptotic cells. In that setting, enhanced levels of autoantigens may 307 promote production of pathogenic autoantibodies recognizing these targets. 
